2017 American Transplant Congress
HCV+ Waitlist Candidates More Likely to Die Waiting for Kidney Transplant from HCV- Donor.
1University of Alabama at Birmingham, Birmingham; 2University of Pennsylvania, Philadelphia
Background: HCV-infected ESRD patients derive a significant survival benefit from kidney transplantation (KT) over remaining on dialysis. Given the high mortality rates on dialysis and…2017 American Transplant Congress
Total Pancreatectomy and Islet Autotransplantation into the Liver of a Patient with Previous Hepatitis C Infection.
Hepatic parenchymal disease such as hepatitis has been considered a relative contraindication to islet transplantation as the islets are infused into the liver. Islet transplantation…2017 American Transplant Congress
Treating Hepatitis C+ Patients Before or After Kidney Transplantation: A Medical Decision Analysis.
Some have recommended that HCV+ kidney wait list patients delay HCV treatment with direct acting antiviral agents (DAAs) with the option of receiving an HCV+/HCV-…2017 American Transplant Congress
An Investigation of Biopsy-Proven De Novo Autoimmune Hepatitis After Hepatitis C Clearance with Direct Acting Antivirals in Liver Transplant Patients.
Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
Direct acting antivirals (DAAs) for hepatitis C virus (HCV) have been widely prescribed to post-liver transplant patients for HCV clearance and are believed to be…2017 American Transplant Congress
Impact of Alemtuzumab Induction on Hepatitis C Treatment Outcomes Post-Renal Transplantation.
University of Maryland Medical Center, Baltimore, MD
BackgroundDirect-acting antiviral agents (DAAs) have improved treatment outcomes for Hepatitis C virus (HCV). Given high rates of treatment success with few side effects, eradication of…2017 American Transplant Congress
Effect of Hepatitis C (HCV) Treatment on Rejection Incidence and Severity in Post-Liver Transplant Patients.
Organ Transplant, Scripps Clinic, La Jolla, CA
Introduction: Hepatitis C remains an important source of morbidity and mortality post liver transplant. Little is known about the long term effects of direct acting…2017 American Transplant Congress
Use of Hepatitis C Infected Organs for Kidney Transplantation: A Medical Decision Analysis.
1Dalhousie University, Halifax, NS, Canada; 2University of Alberta, Edmonton, AB, Canada
Given that Hepatitis C (HCV) can be cured, organs from HCV+ deceased donors might be used in HCV- recipients if treatment at the time of…2017 American Transplant Congress
HCV Eradication with DAA Therapy Should Be Attempted Prior to Liver Transplantation and Does Not Impact HCC Recurrence.
University of Alberta, Edmonton, AB, Canada
Background: Recent advances in the direct-acting antiviral (DAA) treatment of HCV have lead to high rates of HCV eradication, even in patients with decompensated cirrhosis.…2017 American Transplant Congress
Occult Hepatitis C Virus in Recipients of Kidney Transplantation: Prevalence and Clinical Implications.
Occult HCV infection (OCI) is characterized by the presence of HCV- RNA in liver or in peripheral blood mononuclear cells in the absence of serological…2017 American Transplant Congress
Liver Allograft Hepatitis and Graft Loss After Hepatitis C Clearance.
Surgery, University of Maryland School of Medicine, Baltimore, MD
Successful HCV therapies should improve inferior outcomes of liver transplantation (LT) for HCV cirrhosis. We hypothesize certain patients may be predisposed to heterologous immunity that…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 28
- Next Page »